Sign In
Buy LLY
$1,185.71
-7.09 (-0.594%)
At Close: Aug 07, 2026
Alphabet's Isomorphic Labs In Drug Discovery Deals With Eli Lilly, Novartis
03:26pm, Sunday, 07'th Jan 2024
Alphabet unit Isomorphic Labs, which uses AI to help discover new drugs, entered collaboration deals with Eli Lilly and Novartis.
Isomorphic inks deals with Eli Lilly and Novartis for drug discovery
12:51pm, Sunday, 07'th Jan 2024
Isomorphic Labs, the London-based, drug discovery-focused spin-out of Google AI R&D division DeepMind, today announced that it's entered into strategic partnerships with two pharmaceutical giants, Eli
3 Stocks to Make You the Millionaire Next Door: 2024 Edition
04:21pm, Friday, 05'th Jan 2024
Some growth stocks keep powering ahead. While not immune to market downturns, certain stocks seem to decline less and recover faster than other securities.
Eli Lilly's direct drug sales may not upend the industry alone – but others could follow suit
02:37pm, Friday, 05'th Jan 2024
LillyDirect is the latest attempt to simplify what critics call a complex system for distributing, pricing and prescribing prescription drugs.
NVS or LLY: Which Is the Better Value Stock Right Now?
12:47pm, Friday, 05'th Jan 2024
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Novartis (NVS) and Eli Lilly (LLY). But which of these two stocks presents investors with the better value opportunity
Lilly (LLY) Starts Website to Help Access Tirzepatide Drugs
12:02pm, Friday, 05'th Jan 2024
Eli Lilly's (LLY) digital pharmacy is expected to provide patients easy access to its FDA-approved tirzepatide medicines, Mounjaro and Zepbound.
Eli Lilly (LLY) Sees a More Significant Dip Than Broader Market: Some Facts to Know
06:48pm, Thursday, 04'th Jan 2024
In the latest trading session, Eli Lilly (LLY) closed at $614.50, marking a -0.52% move from the previous day.
Eli Lilly's DTC obesity drug push 'not necessarily an industry game changer': Mizuho's Jared Holz
06:25pm, Thursday, 04'th Jan 2024
Jared Holz, Mizuho health care sector strategist, joins 'Fast Money' to talk 'LillyDirect' and what it means for the health care sector as a whole.
Eli Lilly launches LillyDirect: What you need to know
02:23pm, Thursday, 04'th Jan 2024
The "Halftime Report" Investment Committee debate what the direct-to-consumer move means for the obesity drugmaker.
Eli Lilly launches website, home delivery option for Wegovy alternative Zepbound
11:48am, Thursday, 04'th Jan 2024
Lilly said its direct-to-consumer service will also be available for patients with diabetes and migraine, with the website's pharmacy page listing migraine drug Emgality, insulin and similar products
Eli Lilly launches 'LillyDirect': What this means for the pharma space
10:54am, Thursday, 04'th Jan 2024
Dr. Scott Gottlieb, former FDA commissioner and CNBC contributor, joins 'Squawk on the Street' to discuss Eli Lilly's launch of 'LillyDirect,' who gets hurt the most by the company's move, and more.
Eli Lilly Stock Hits Record on Drug Prescription Website
10:47am, Thursday, 04'th Jan 2024
Eli Lilly And Co (NYSE:LLY) today launched LillyDirect, a website that allows consumers with obesity to get prescriptions for its weight-loss drug Zepbound via telehealth, and offers home delivery o
Dr. Kavita Patel: Eli Lilly's direct-to-consumer portal will help patients get medications faster
10:06am, Thursday, 04'th Jan 2024
Dr. Kavita Patel, former White House health policy director, joins 'Squawk Box' to discuss news of Eli Lilly's launch of 'LillyDirect', an online direct-to-consumer pharmacy allowing people to get med
Pharmaceutical First: Eli Lilly Website Will Prescribe Weight Loss Drugs Through Service
09:51am, Thursday, 04'th Jan 2024
Drugmaker Eli Lilly has launched a new website specifically for prescribing weight loss drugs through a telehealth service less than a month after the company's new injectable, Zepbound, became availa
Eli Lilly stock climbs in 2024 on weight-loss drug outlook
09:48am, Thursday, 04'th Jan 2024
Eli Lilly and Co (NYSE:LLY) shares have gained more than 8% during the past five trading sessions on investor enthusiasm over prospects for the company's weight-loss drug Zepbound. In a client upda
